Colo205 Orthotopic Mouse Model Service for Colon Cancer

The Colo205 orthotopic mouse model recapitulates a BRAF^V600E-driven, microsatellite-stable human colorectal adenocarcinoma within the murine cecal wall, offering a physiologically grounded platform for evaluating targeted agents, combination regimens, and metastatic biology in a setting that mirrors the human disease anatomically and molecularly. Alfa Cytology constructs this human xenograft system with meticulous surgical precision and stringent cell line quality assurance, providing researchers with reproducible tumor kinetics, validated hepatic metastasis patterns, and comprehensive endpoint histopathology to advance preclinical colon cancer drug development programs.

Overview of Colo205 Orthotopic Mouse Model for Colon Cancer

The Colo205 cell line was originally established by George Moore in 1975 from the ascitic fluid of a 70-year-old male patient with advanced colorectal adenocarcinoma classified as Dukes Grade D. Genetically, Colo205 is defined by a homozygous BRAF^V600E oncogenic mutation that constitutively activates the MAPK signaling cascade, while retaining wild-type KRAS and TP53 loci—a molecular signature that places it within the consensus molecular subtype 3 (CMS3) / iCMS3-MSS spectrum, exhibiting intermediate characteristics of both CMS2 and CMS3 human colorectal cancers. The line also harbors biallelic APC truncation with large-scale chromosomal alterations, a hypertriploid karyotype with a modal chromosome number of 71–78, and microsatellite stable (MSS) status. When propagated as an orthotopic xenograft, Colo205 cells engraft reliably into the cecal wall of immunodeficient mice, forming moderately differentiated adenocarcinomas that invade locally and disseminate hematogenously to the liver and lungs, thereby replicating the natural metastatic trajectory observed in human advanced colorectal disease.

Fig 1. Near-infrared optical imaging of epidermal growth factor receptor (EGFR) expression levels in COLO205 orthotopic tumors and human biopsies, enabling non-invasive visualization of receptor distribution and quantitative assessment of EGFR-targeted therapeutic engagement in BRAF-mutant colorectal cancer preclinical models. (Cohen, Gadi, et al., 2013)

Orthotopic implantation of Colo205 into the cecal wall—whether by direct cell suspension injection or by surgical grafting of subcutaneous tumor fragments—establishes a tumor-stromal interface that preserves the serosal, muscular, and mucosal layers of the colonic wall, fostering physiologic angiogenesis, lymphatic drainage, and peritoneal seeding patterns absent in flank subcutaneous models. The cecal mesenteric triangle, where vasculature and lymphatics converge, serves as a particularly favorable implantation site that promotes portal venous metastasis to the liver. Because Colo205 retains wild-type TP53 and exhibits pronounced apoptotic responsiveness to targeted stress, this model is especially valuable for dissecting BRAF/MEK inhibitor efficacy, EGFR feedback resistance mechanisms, and combination strategies incorporating PI3K/AKT pathway blockade. The resulting orthotopic system offers a robust, clinically translatable preclinical framework for interrogating drug pharmacodynamics, tumor regression kinetics, and adaptive resistance in BRAF-mutant colorectal cancer.

Cell Line Information: Colo205

Colo205 is a human colorectal adenocarcinoma cell line with a well-defined molecular architecture and mixed growth characteristics. The following table details its biological origin, genetic profile, and culture specifications:

Our Services

Alfa Cytology offers full-spectrum Colo205 orthotopic model services spanning authenticated cell bank management, cecal wall surgical implantation with validated fragment grafting or direct injection techniques, longitudinal tumor monitoring, and terminal multimodal endpoint analysis. Our team ensures each production batch is STR-verified, mycoplasma-negative, and phenotypically authenticated before implantation, while surgical procedures are conducted under AAALAC-accredited standards with rigorous perioperative care. We support BRAF/MEK inhibitor programs, EGFR combination studies, and apoptosis-focused therapeutic pipelines with customized study designs, pharmacokinetic bridging, and GLP-compliant documentation packages tailored to your preclinical milestones.

Workflow of Colo205 Orthotopic Mouse Model Construction

Construction of a reproducible Colo205 orthotopic colon cancer model integrates cell culture fidelity, sterile surgical technique, and standardized endpoint harvesting. Our protocol is optimized for consistent engraftment, minimal perioperative loss, and robust metastatic readouts suitable for BRAF-targeted therapeutic assessment. The workflow proceeds through the following stages:

1. Cell Line Authentication and Expansion: Colo205 master stocks are revived and expanded in antibiotic-free RPMI 1640 medium. Each production lot is subjected to STR profiling against the reference database, mycoplasma PCR screening, and in vitro phenotypic validation to confirm BRAF^V600E expression and apoptotic responsiveness before surgical use.
2. Pre-Implantation Tumor Tissue Preparation: Two validated engraftment routes are employed. Route A (direct cell injection): logarithmic-phase Colo205 cells are harvested, washed in sterile PBS, and resuspended at 1–2 x 10⁷ cells/mL in ice-cold PBS or 50% Matrigel for a 30 μL cecal wall inoculum. Route B (tumor fragment grafting): subcutaneous donor tumors are grown in nude mice, excised at ~100–150 mm³, necrotic tissue is trimmed away, and fragments are sectioned to 0.15 mg pieces using a sterile scalpel with weight verified on a precision microbalance (±0.05 mg deviation).
3. Recipient Mouse Preparation and Anesthesia: Female athymic nude mice (BALB/c nu/nu, 6–8 weeks, 18–22 g) are acclimated for 7 days under SPF barrier conditions. On the procedure day, general anesthesia is induced with 1–2% isoflurane in medical oxygen delivered via nose cone. The ventral abdomen is shaved, cleansed sequentially with povidone-iodine and 70% ethanol, and draped sterilely.
4. Cecal Wall Orthotopic Implantation: A 3–5 mm lower midline laparotomy exposes the cecum. For Route A, a 30-gauge Hamilton micro-syringe delivers the cell suspension into the subserosal muscularis of the cecal wall at the mesenteric triangle, where the wall lacks serosal covering and vascular ingress facilitates engraftment. For Route B, a tumor fragment is positioned on the cecal serosa and secured with 8-0 absorbable sutures or a biocompatible tissue adhesive (~10 μL, drying 10–15 s). The cecum is returned to the peritoneal cavity, and the abdominal wall and skin are closed with 5-0 absorbable sutures or surgical staples.
5. Post-Operative Recovery and Clinical Surveillance: Mice recover on a heated pad until fully ambulatory. Post-operative analgesia (buprenorphine 0.05–0.1 mg/kg, s.c.) is administered according to IACUC guidelines. Daily monitoring for 7–10 days assesses wound integrity, body weight, food intake, and abdominal distension. Humane endpoints include >20% body weight loss, wound dehiscence, or signs of severe distress.
6. Tumor Establishment Monitoring and Randomization: Tumor engraftment is confirmed by palpable abdominal mass or by bioluminescence imaging (if luciferase-expressing derivatives are used) beginning 7–10 days post-implantation. Mice with confirmed tumors are enrolled and randomized into treatment cohorts once mean tumor burden reaches a predefined threshold (e.g., palpable mass ~50–100 mm³ or bioluminescent flux ~1–5 x 10⁶ photons/sec).
7. Therapeutic Dosing and Longitudinal Assessment: Test articles are administered per protocol via oral gavage, intravenous, intraperitoneal, or subcutaneous routes. Tumor dimensions are measured twice weekly by caliper (length x width² x 0.5 = mm³). Body weights and clinical observations are recorded three times weekly. Blood samples may be collected via submandibular bleed for pharmacokinetic or CEA biomarker analysis at designated intervals.
8. Necropsy, Tumor Harvest, and Comprehensive Endpoint Analysis: At study termination, mice are humanely euthanized. The primary cecal tumor is excised, weighed, photographed, and dimensions recorded. The abdominal cavity is inspected macroscopically for peritoneal carcinomatosis. Metastatic target organs (liver, lung, mesenteric lymph nodes, diaphragm, spleen) are harvested. Tissues are fixed in 10% neutral buffered formalin for H&E histology, or snap-frozen in liquid nitrogen for molecular analysis. Immunohistochemistry for Ki-67, cleaved caspase-3, CD31, BRAFV600E, phospho-ERK1/2, and CEA provides mechanistic insight into proliferation, apoptosis, angiogenesis, MAPK pathway suppression, and tumor differentiation status.

Fig 2. Colo205 Orthotopic Mouse Model construction workflow.

Case Study-Colo205 Orthotopic Mouse Model Development

In a recent preclinical evaluation, the Colo205 orthotopic model was utilized to assess the efficacy of a selective BRAF inhibitor in combination with an EGFR monoclonal antibody, a regimen reflecting current clinical strategies for BRAF-mutant metastatic colorectal cancer. Colo205 cells were implanted into the cecal wall of athymic nude mice via subserosal injection, with tumor establishment confirmed by palpation within 10–14 days. Upon reaching a standardized tumor volume, mice were randomized to receive vehicle, BRAF inhibitor monotherapy, EGFR antibody monotherapy, or the combination for 3 weeks. The combination arm exhibited marked suppression of primary cecal tumor growth relative to both monotherapy and vehicle groups, accompanied by reduced tumor weight at necropsy and diminished phospho-ERK1/2 immunohistochemical staining. Importantly, macroscopic inspection and H&E analysis of liver tissue revealed fewer metastatic nodules in the combination cohort compared to vehicle controls, suggesting that dual MAPK/EGFR blockade not only restrains local tumor expansion but also attenuates hematogenous dissemination to the liver. These data highlight the capacity of the Colo205 orthotopic platform to capture both primary tumor pharmacodynamics and metastatic outcome measures within a single in vivo study, providing actionable preclinical intelligence for BRAF-mutant colorectal cancer drug development.

Why Choose Alfa Cytology?

Preclinical evaluation of BRAF-mutant colorectal cancer therapeutics demands a model that faithfully replicates the molecular drivers, anatomical site, and metastatic behavior of human disease. Alfa Cytology structures its Colo205 orthotopic service around these imperatives, delivering distinct value at every stage of your program:

• We maintain authenticated, low-passage Colo205 master and working cell banks with documented STR profiles, routine mycoplasma surveillance, and BRAF^V600E allele-specific validation, ensuring genetic fidelity and batch-to-batch consistency.
• Our surgical team employs both direct cecal wall injection and tumor fragment grafting techniques with proven engraftment efficiency, leveraging the cecal mesenteric triangle to maximize portal venous metastasis modeling and minimize inter-animal variability.
• Endpoint analysis extends beyond standard caliper measurements to include quantitative histopathology, IHC-based MAPK pathway biomarker assessment, and CEA biomarker quantification, yielding mechanistic data that directly inform clinical biomarker strategy.
• Study protocols are architected around your compound class—whether BRAF/MEK inhibitors, EGFR combination regimens, PI3K/AKT pathway modulators, or apoptosis-inducing agents—with flexible dosing schedules and pharmacokinetic integration.
• We provide digital whole-slide pathology with remote access, enabling real-time peer review, AI-assisted image quantification, and seamless data transfer into your internal electronic data capture systems.
• Comprehensive study deliverables include raw data packages, statistical analysis plans, and GLP-compliant study reports upon request, facilitating smooth progression from preclinical efficacy studies to IND-enabling toxicology and regulatory documentation.

Contact Us

If your colorectal cancer research program targets the BRAF-mutant population and requires an orthotopic model with validated hepatic metastasis and deep molecular endpoint characterization, we invite you to reach out to us for a confidential project discussion. The scientific team at Alfa Cytology is prepared to design a customized Colo205 orthotopic study aligned with your therapeutic mechanism, compound properties, and regulatory roadmap. Contact us today to request a detailed proposal, feasibility timeline, and pricing structure—let us advance your BRAF-targeted pipeline with rigorous, publication-ready preclinical data.

For research use only. Not intended for any clinical use.